(BIIB) Biogen - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09062X1037
Stock: Neurology Drugs, Biosimilars, Rare Diseases, Alzheimers
Total Rating 57
Risk 92
Buy Signal -0.01
| Risk 5d forecast | |
|---|---|
| Volatility | 29.4% |
| Relative Tail Risk | -4.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.80 |
| Alpha | 17.25 |
| Character TTM | |
|---|---|
| Beta | 0.699 |
| Beta Downside | 0.613 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.35% |
| CAGR/Max DD | -0.18 |
EPS (Earnings per Share)
Revenue
Description: BIIB Biogen March 05, 2026
Biogen Inc. (BIIB) is a biotechnology company that develops and delivers therapies globally. Its product portfolio includes treatments for neurological disorders like multiple sclerosis (MS), spinal muscular atrophy, Friedreichs Ataxia, and Alzheimers disease.
The company also offers biosimilars, which are crucial in the pharmaceutical sector for increasing access to biologic medicines by offering more affordable alternatives. Biogens pipeline includes therapies for conditions such as amyotrophic lateral sclerosis, postpartum depression, various lymphomas, and rheumatoid arthritis.
Biogen frequently engages in collaborations and licensing agreements with other pharmaceutical and biotechnology firms, a common strategy in the industry to share research and development costs and expand product pipelines. To gain a deeper understanding of Biogens market position and financial health, further research on platforms like ValueRay is recommended.
Headlines to watch out for
- Alzheimers drug Leqembi sales growth impacts revenue
- Multiple sclerosis drug sales face increasing competition
- Biosimilar portfolio expansion drives international revenue
- Pipeline development and regulatory approvals influence future growth
- Collaboration agreements with partners affect R&D costs
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.70 > 1.0 |
| NWC/Revenue: 57.33% < 20% (prev 19.93%; Δ 37.41% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.20b > Net Income 1.29b |
| Net Debt (3.94b) to EBITDA (3.10b): 1.27 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (146.7m) vs 12m ago 0.41% < -2% |
| Gross Margin: 70.47% > 18% (prev 0.72%; Δ 6.97k% > 0.5%) |
| Asset Turnover: 34.13% > 50% (prev 34.50%; Δ -0.37% > 0%) |
| Interest Coverage Ratio: 8.09 > 6 (EBITDA TTM 3.10b / Interest Expense TTM 267.5m) |
Altman Z'' 5.95
| A: 0.19 (Total Current Assets 8.97b - Total Current Liabilities 3.35b) / Total Assets 29.44b |
| B: 0.70 (Retained Earnings 20.55b / Total Assets 29.44b) |
| C: 0.08 (EBIT TTM 2.17b / Avg Total Assets 28.74b) |
| D: 1.82 (Book Value of Equity 20.37b / Total Liabilities 11.18b) |
| Altman-Z'' Score: 5.95 = AAA |
Beneish M -3.06
| DSRI: 0.99 (Receivables 1.87b/1.87b, Revenue 9.81b/9.68b) |
| GMI: 1.03 (GM 70.47% / 72.34%) |
| AQI: 0.96 (AQ_t 0.58 / AQ_t-1 0.61) |
| SGI: 1.01 (Revenue 9.81b / 9.68b) |
| TATA: -0.03 (NI 1.29b - CFO 2.20b) / TA 29.44b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of BIIB shares?
As of March 18, 2026, the stock is trading at USD 185.29 with a total of 790,156 shares traded.
Over the past week, the price has changed by -1.66%, over one month by -5.28%, over three months by +7.66% and over the past year by +29.09%.
Over the past week, the price has changed by -1.66%, over one month by -5.28%, over three months by +7.66% and over the past year by +29.09%.
Is BIIB a buy, sell or hold?
Biogen has received a consensus analysts rating of 3.81.
Therefore, it is recommended to buy BIIB.
- StrongBuy: 13
- Buy: 4
- Hold: 20
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BIIB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 205.7 | 11% |
| Analysts Target Price | 205.7 | 11% |
BIIB Fundamental Data Overview March 16, 2026
P/E Trailing = 20.6542
P/E Forward = 11.5607
P/S = 2.6939
P/B = 1.4594
P/EG = 3.5572
Revenue TTM = 9.81b USD
EBIT TTM = 2.17b USD
EBITDA TTM = 3.10b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 80.4m USD (from shortTermDebt, last quarter)
Debt = 6.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.94b USD (from netDebt column, last quarter)
Enterprise Value = 29.78b USD (26.64b + Debt 6.95b - CCE 3.82b)
Interest Coverage Ratio = 8.09 (Ebit TTM 2.17b / Interest Expense TTM 267.5m)
EV/FCF = 13.92x (Enterprise Value 29.78b / FCF TTM 2.14b)
FCF Yield = 7.18% (FCF TTM 2.14b / Enterprise Value 29.78b)
FCF Margin = 21.80% (FCF TTM 2.14b / Revenue TTM 9.81b)
Net Margin = 13.18% (Net Income TTM 1.29b / Revenue TTM 9.81b)
Gross Margin = 70.47% ((Revenue TTM 9.81b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 78.23% (prev 64.29%)
Tobins Q-Ratio = 1.01 (Enterprise Value 29.78b / Total Assets 29.44b)
Interest Expense / Debt = 0.97% (Interest Expense 67.5m / Debt 6.95b)
Taxrate = 7.71% (108.1m / 1.40b)
NOPAT = 2.00b (EBIT 2.17b * (1 - 7.71%))
Current Ratio = 2.68 (Total Current Assets 8.97b / Total Current Liabilities 3.35b)
Debt / Equity = 0.38 (Debt 6.95b / totalStockholderEquity, last quarter 18.26b)
Debt / EBITDA = 1.27 (Net Debt 3.94b / EBITDA 3.10b)
Debt / FCF = 1.84 (Net Debt 3.94b / FCF TTM 2.14b)
Total Stockholder Equity = 17.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 1.29b / Total Assets 29.44b)
RoE = 7.28% (Net Income TTM 1.29b / Total Stockholder Equity 17.77b)
RoCE = 9.00% (EBIT 2.17b / Capital Employed (Equity 17.77b + L.T.Debt 6.29b))
RoIC = 8.31% (NOPAT 2.00b / Invested Capital 24.06b)
WACC = 6.92% (E(26.64b)/V(33.59b) * Re(8.49%) + D(6.95b)/V(33.59b) * Rd(0.97%) * (1-Tc(0.08)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF] Terminal Value 83.82% ; FCFF base≈2.29b ; Y1≈2.63b ; Y5≈3.69b
[DCF] Fair Price = 522.7 (EV 80.65b - Net Debt 3.94b = Equity 76.71b / Shares 146.8m; r=6.92% [WACC]; 5y FCF grow 17.62% → 2.90% )
EPS Correlation: -40.56 | EPS CAGR: -18.97% | SUE: 0.63 | # QB: 0
Revenue Correlation: -39.75 | Revenue CAGR: -2.76% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.32 | Chg7d=+0.000 | Chg30d=+0.032 | Revisions Net=+7 | Analysts=23
EPS current Year (2026-12-31): EPS=15.69 | Chg7d=+0.000 | Chg30d=+0.021 | Revisions Net=+13 | Growth EPS=+2.7% | Growth Revenue=-4.7%
EPS next Year (2027-12-31): EPS=16.24 | Chg7d=+0.000 | Chg30d=-0.076 | Revisions Net=+6 | Growth EPS=+3.5% | Growth Revenue=-0.7%
[Analyst] Revisions Ratio: +0.47 (11 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 8.5% - Earnings Yield 4.8%)
[Growth] Growth Spread = -13.1% (Analyst -9.5% - Implied 3.6%)
P/E Forward = 11.5607
P/S = 2.6939
P/B = 1.4594
P/EG = 3.5572
Revenue TTM = 9.81b USD
EBIT TTM = 2.17b USD
EBITDA TTM = 3.10b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 80.4m USD (from shortTermDebt, last quarter)
Debt = 6.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.94b USD (from netDebt column, last quarter)
Enterprise Value = 29.78b USD (26.64b + Debt 6.95b - CCE 3.82b)
Interest Coverage Ratio = 8.09 (Ebit TTM 2.17b / Interest Expense TTM 267.5m)
EV/FCF = 13.92x (Enterprise Value 29.78b / FCF TTM 2.14b)
FCF Yield = 7.18% (FCF TTM 2.14b / Enterprise Value 29.78b)
FCF Margin = 21.80% (FCF TTM 2.14b / Revenue TTM 9.81b)
Net Margin = 13.18% (Net Income TTM 1.29b / Revenue TTM 9.81b)
Gross Margin = 70.47% ((Revenue TTM 9.81b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 78.23% (prev 64.29%)
Tobins Q-Ratio = 1.01 (Enterprise Value 29.78b / Total Assets 29.44b)
Interest Expense / Debt = 0.97% (Interest Expense 67.5m / Debt 6.95b)
Taxrate = 7.71% (108.1m / 1.40b)
NOPAT = 2.00b (EBIT 2.17b * (1 - 7.71%))
Current Ratio = 2.68 (Total Current Assets 8.97b / Total Current Liabilities 3.35b)
Debt / Equity = 0.38 (Debt 6.95b / totalStockholderEquity, last quarter 18.26b)
Debt / EBITDA = 1.27 (Net Debt 3.94b / EBITDA 3.10b)
Debt / FCF = 1.84 (Net Debt 3.94b / FCF TTM 2.14b)
Total Stockholder Equity = 17.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 1.29b / Total Assets 29.44b)
RoE = 7.28% (Net Income TTM 1.29b / Total Stockholder Equity 17.77b)
RoCE = 9.00% (EBIT 2.17b / Capital Employed (Equity 17.77b + L.T.Debt 6.29b))
RoIC = 8.31% (NOPAT 2.00b / Invested Capital 24.06b)
WACC = 6.92% (E(26.64b)/V(33.59b) * Re(8.49%) + D(6.95b)/V(33.59b) * Rd(0.97%) * (1-Tc(0.08)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF] Terminal Value 83.82% ; FCFF base≈2.29b ; Y1≈2.63b ; Y5≈3.69b
[DCF] Fair Price = 522.7 (EV 80.65b - Net Debt 3.94b = Equity 76.71b / Shares 146.8m; r=6.92% [WACC]; 5y FCF grow 17.62% → 2.90% )
EPS Correlation: -40.56 | EPS CAGR: -18.97% | SUE: 0.63 | # QB: 0
Revenue Correlation: -39.75 | Revenue CAGR: -2.76% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.32 | Chg7d=+0.000 | Chg30d=+0.032 | Revisions Net=+7 | Analysts=23
EPS current Year (2026-12-31): EPS=15.69 | Chg7d=+0.000 | Chg30d=+0.021 | Revisions Net=+13 | Growth EPS=+2.7% | Growth Revenue=-4.7%
EPS next Year (2027-12-31): EPS=16.24 | Chg7d=+0.000 | Chg30d=-0.076 | Revisions Net=+6 | Growth EPS=+3.5% | Growth Revenue=-0.7%
[Analyst] Revisions Ratio: +0.47 (11 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 8.5% - Earnings Yield 4.8%)
[Growth] Growth Spread = -13.1% (Analyst -9.5% - Implied 3.6%)